Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma

In combination with a chemotherapy regimen (l-asparaginase, vincristine, cyclophosphamide, doxorubicin, lomustine and prednisone), APAVAC immunotherapy significantly prolongs the time to progression (TTP) of dogs with advanced indolent lymphoma.